drugset / Trial / NCT01682213
Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation
Phase 2
Completed
23 enrolled
Memorial Sloan Kettering Cancer Center
National Comprehensive Cancer Network · collabNovartis · collab
NaSingle-groupOpen-labelTreatment
Summary
In this study, the investigator's want to find out if dabrafenib can stop stage IIIC melanoma from coming back after surgery.
Timeline
- Start
- 2012-09
- Primary completion
- 2019-05
- Completion
- 2019-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dabrafenib | Small molecule | 150 mg | Oral |